

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

March 4, 2020

**Location: Learning Resource Center
Fairmeadows Room
3550 Mills Civic Parkway
West Des Moines, Iowa, 50265**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) November 2019 DUR Recommendation Letter to DHS
 - c) Follow-Up from Previous Meeting(s)
 - i. Linezolid Claims Data
 - ii. Pramlintide Acetate (Symlin) Claims Data
 - iii. Crisaborole (Eucrisa) Claims Data and Prior Authorization Data
 - d) Commission Recommendations for Retrospective DUR Agenda Topics
3. IME Pharmacy Update
4. Prevalence Report Summaries
 - a) Amerigroup
 - b) Iowa Total Care
 - c) Fee-for-Service
 - d) Comparative Summary
5. Public Comment* (See Speaker Conflict of Interest Disclosure Form)
6. ProDUR Edits
 - a) Review of Current & Proposed Opioid Quantity Limits - Second Review
7. Retrospective DUR
 - a) Data Presentation(s)
 - i. Duplicate SSRIs

- ii. High Dose Gabapentin
- b) Proposal(s)
 - i. Duplicate SNRIs
 - ii. Gabapentin and Baclofen
- 8. Break (10 minutes)
- 9. Prior Authorization
 - a) Cystic Fibrosis Agents, Oral – Initial Review
 - b) Valsartan/ Sacubitril (Entresto) – Initial Review
 - c) Novel Oral Anticoagulants – Initial Review
 - d) Voxelotor (Oxbryta) – Initial Review
 - e) IL-5 Antagonists – Initial Review
 - f) Acute Migraine Treatments – Initial Review
 - g) Insulin, Pre-Filled Pens – Removal of Prior Authorization – Initial Review
 - h) Linezolid (Zyvox) – Second Review
 - i) Dupilumab (Dupixent) – Second Review
 - j) Biologicals for Axial Spondyloarthritis – Second Review
 - k) Ivabradine (Corlanor) – Second Review
 - l) Chronic Pain Syndromes – Removal of Prior Authorization - Second Review
 - m) Anti-Diabetic Non-Insulin Agents – Second Review
- 10. Miscellaneous
 - a) DUR Digest Vol. 32, No. 2 – Initial Review
 - b) MedWatch
- 11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

**Next Meeting
May 6, 2020
Department of the Blind
524 4th Street, Des Moines, IA 50309**